Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.400 AlteredExpression phenotype BEFREE Aromatase knockdown in PC3 cells reduced invasiveness and decreased metastasis-related gene expression. 31499120 2019
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.400 Biomarker phenotype BEFREE CD5 antigen-like (CD5L), clusterin (CLUS) and C-C motif chemokine 14 (CCL14)], in transcription (e.g. protein SSX3 and signal transducer and activator of transcription 3 (STAT3)], in invasion and metastasis (e.g. alpha-2-HS-glycoprotein (FETUA)], in estrogen synthesis [aromatase (CYP19A1)] and other diverse biological roles [e.g. actin-related protein 2/3 complex subunit 4 (ARPC4), dual specificity mitogen-activated protein kinase kinase 4 (MP2K4), ectoderm-neural cortex protein 1 (ENC1), and matrix metalloproteinase-27 (MMP27)]. 30850364 2019
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.400 Biomarker phenotype BEFREE Our patient had received chemotherapy and hormonal therapy (tamoxifen for 3 years and letrozole in the following 3 years) for her primary cancer and developed an orbital metastasis while she was under aromatase inhibitor-based therapy. 30621656 2019
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.400 Biomarker phenotype BEFREE Increased leptin, which upregulates estrogen receptor alpha (ERα) and aromatase, enhances estrogen bioavailability and signaling in estrogen receptor positive (ER⁺) breast cancer (BC) tumor growth and metastasis. 30897853 2019
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.400 GeneticVariation phenotype BEFREE Aromatase inhibitors were superior in preventing contralateral cancers, with a small impact on the risk of distant metastatic disease. 31212043 2019
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.400 Biomarker phenotype BEFREE Increased aromatase in TS was significantly associated with adverse pathologic variables including higher pathologic pT, positive lymph node metastasis (pN), lymphovascular invasion (LVI), and distant metastasis. 29303414 2018
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.400 Biomarker phenotype BEFREE In premenopausal women treated for breast cancer, endocrine therapy combining an aromatase inhibitor (AI) and a gonadotropin-releasing hormone (GnRH) agonist (GA) for ovarian suppression may be indicated in high-risk or in metastatic cancer. 29510273 2018
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.400 AlteredExpression phenotype BEFREE Women diagnosed with breast cancer metastases within a period of 6 months and before the end of follow-up were matched (1:1) by age, index year, physician, type of hormonal therapy (tamoxifen or aromatase inhibitors) and follow-up time (in months) with women without metastases. 29845476 2018
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.400 Biomarker phenotype CTD_human Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ERα metastatic breast cancer. 28112739 2017
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.400 Biomarker phenotype BEFREE Aromatase inhibitors represent an effective endocrine treatment for patients with hormone receptor-positive breast cancer, in early stage and in metastatic disease. 27561703 2017
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.400 Biomarker phenotype BEFREE Until recently, classical endocrine agents such as tamoxifen, steroidal and nonsteroidal aromatase inhibitors and fulvestrant have been widely used in postmenopausal patients to treat locally advanced or metastatic disease. 28717399 2017
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.400 Biomarker phenotype BEFREE Retrospective analyses of <i>ESR1</i> mutations in baseline plasma circulating tumor DNA from clinical trials suggest that these mutations are prognostic of poor overall survival and predictive of resistance to aromatase inhibitors in metastatic disease. 29234250 2017
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.400 Biomarker phenotype BEFREE Retrospective analyses of ESR1 mutations in baseline plasma circulating tumor DNA from completed clinical trials suggest that these mutations are prognostic and predictive of resistance to aromatase inhibitors in metastatic disease. 28374222 2017
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.400 Biomarker phenotype BEFREE In the 135 assessable patients (93 % were receiving an aromatase inhibitor; biomarker assessment had been performed on primary tumors in 77 cases, on metastases in 23 and on both in 35), median TTP was 16 months (median follow-up 43 months). 26012644 2015
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.400 GeneticVariation phenotype BEFREE In this study, we found that MRTF-A expression was upregulated in metastatic anaplastic thyroid cancer tissues, compared with primary cancer tissues and it promoted metastasis-relevant traits in vitro. miR-206 was negatively associated with metastasis in anaplastic cancer and it degraded MRTF-A by targeting its 3'-UTR in ARO anaplastic thyroid cancer cells. 25955685 2015
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.400 Biomarker phenotype BEFREE Therefore, in this study, we first immunolocalized aromatase using immunohistochemistry in patients with liver cirrhosis, steatosis, hepatitis, HCC, and metastasis liver carcinoma (MLC) in order to study the detailed status of intrahepatic aromatase. 23930207 2013
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.400 Biomarker phenotype BEFREE The mutation status was studied for their relationship with metastasis-free survival (MFS) in 342 untreated lymph node-negative (LNN) patients and to time to progression (TTP) in estrogen receptor (ER)-positive patients with metastatic disease treated with first-line tamoxifen (N = 447) or aromatase inhibitors (AIs; N = 84). 23592373 2013
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.400 AlteredExpression phenotype LHGDN Levels of aromatase, STS and 17beta-HSD(1) mRNA are up-regulated in soft tissue metastases compared to those in primary tumors, suggesting that intra-tumoral estrogen synthesis may play a significant role in the growth stimulation of tumor cells in soft tissue metastases as in primary tumors. 16556483 2006
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.400 AlteredExpression phenotype BEFREE Increased levels of CYP19 mRNA expression positively correlated with disease progression as levels were significantly higher in samples of patients who had distant metastasis and local recurrence and/or died of breast related causes when compared to those who were disease free for >10 years (p=0.0015). 16541304 2006
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.400 AlteredExpression phenotype BEFREE Expression of the estrogen-synthesizing genes aromatase, steroid sulfatase (STS) and 17beta-hydroxysteroid dehydrogenase type1 (17beta-HSD(1)) has been shown to be up-regulated in primary breast cancer tissue but their expression status in metastatic tumor tissue has yet to be determined. 16556483 2006
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.400 Biomarker phenotype BEFREE We identified a subregion defined by microsatellite marker CYP19 (15q21.1) that showed significantly higher frequencies of allelic imbalance in metastases and recurrences (57.6%) when compared to primary carcinomas (8.9%; p<0.0001). 12794759 2003
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.400 Biomarker phenotype BEFREE Aromatase inhibitors have important roles in optimal management of postmenopausal patients with hormone-responsive metastases in both the adjuvant and advanced-disease settings. 12514567 2003
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.400 AlteredExpression phenotype BEFREE The basic carcinogenic processes are: (1) constitutive prostaglandin biosynthesis and formation of mutagenic oxygen and nitrogen free radicals responsible for tumor initiation; (2) PGE-2-induced expression of aromatase and constitutive estrogen biosynthesis which sustains mitogenesis and tumor promotion; and (3) PGE-2-induced expression of vascular endothelial growth factor which stimulates angiogenesis and tumor metastasis. 10465664 1999